Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 19/20 | 0.53 |
| ▸ | S1PR5 | Q9H228 | 7/20 | 0.51 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.51 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.43 |
| ▸ | PRKX | P51817 | 1/20 | 0.42 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.42 |
| ▸ | CDK7 | P50613 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25269994 | 1.00 | S1PR1 (0.53) | S1PR1S1PR5S1PR4S1PR3PDGFRA | |
| SCHEMBL25270926 | 0.92 | S1PR1 (0.51) | S1PR1S1PR5S1PR4 | |
| SCHEMBL30488250 | 0.92 | S1PR1 (0.51) | S1PR1S1PR5S1PR4 | |
| SCHEMBL30488279 | 0.87 | S1PR1 (0.49) | S1PR1S1PR5S1PR3PDGFRAPRKX | |
| SCHEMBL25229195 | 0.87 | S1PR1 (0.49) | S1PR1S1PR5S1PR3PDGFRAPRKX | |
| SCHEMBL25269349 | 0.86 | S1PR1 (0.51) | S1PR1S1PR5S1PR4S1PR3PDGFRA | |
| SCHEMBL30488278 | 0.86 | S1PR1 (0.51) | S1PR1S1PR5S1PR4S1PR3PDGFRA | |
| SCHEMBL25226963 | 0.85 | S1PR1 (0.63) | S1PR1S1PR5S1PR4 | |
| SCHEMBL30488211 | 0.85 | S1PR1 (0.63) | S1PR1S1PR5S1PR4 | |
| SCHEMBL26291127 | 0.84 | S1PR1 (0.52) | S1PR1S1PR5S1PR4S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376048-A1 | Carboxylic Acid Containing Indanyl Compounds for the Treatment of Neurodegenerative Diseases | CELGENE CORPORATION (US) | 2024-11-14 | — | — | US | disclosed |
| EP-4444697-A1 | CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORPORATION (US) | 2024-10-16 | — | — | EP | disclosed |
| CN-118632834-A | Indanyl compounds containing carboxylic acids for the treatment of neurodegenerative diseases | 细胞基因公司 | 2024-09-10 | — | — | CN | disclosed |
| WO-2023107563-A1 | CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORPORATION (US) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376048-A1 | Carboxylic Acid Containing Indanyl Compounds for the Treatment of Neurodegenerative Diseases | S1PR5, S1PR2, LPAR5 | S1PR1 4/4885S1PR5 1/4885S1PR4 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.